BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 35 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $28,000 | +7.7% | 6,600 | 0.0% | 0.00% | – |
| Q3 2019 | $26,000 | 0.0% | 6,600 | 0.0% | 0.00% | – |
| Q2 2019 | $26,000 | +30.0% | 6,600 | +43.5% | 0.00% | – |
| Q1 2019 | $20,000 | +66.7% | 4,600 | +27.8% | 0.00% | – |
| Q4 2018 | $12,000 | -7.7% | 3,600 | 0.0% | 0.00% | – |
| Q3 2018 | $13,000 | -7.1% | 3,600 | +2.9% | 0.00% | – |
| Q2 2018 | $14,000 | +75.0% | 3,500 | +40.0% | 0.00% | – |
| Q1 2018 | $8,000 | -20.0% | 2,500 | 0.0% | 0.00% | – |
| Q4 2017 | $10,000 | +25.0% | 2,500 | +25.0% | 0.00% | – |
| Q3 2017 | $8,000 | +33.3% | 2,000 | +33.3% | 0.00% | – |
| Q2 2017 | $6,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q1 2017 | $6,000 | +50.0% | 1,500 | 0.0% | 0.00% | – |
| Q4 2016 | $4,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q3 2016 | $4,000 | +33.3% | 1,500 | 0.0% | 0.00% | – |
| Q2 2016 | $3,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 239,000 | $2,679,000 | 0.48% |
| EAM Investors, LLC | 81,854 | $918,000 | 0.20% |
| CFO4Life Group, LLC | 12,003 | $135,000 | 0.05% |
| Phoenix Holdings Ltd. | 104,782 | $1,112,000 | 0.05% |
| WINTON GROUP Ltd | 118,487 | $1,328,000 | 0.03% |
| Merit Financial Group, LLC | 28,731 | $322,000 | 0.03% |
| HighPoint Advisor Group LLC | 13,533 | $151,000 | 0.03% |
| SHANDA ASSET MANAGEMENT HOLDINGS Ltd | 23,000 | $258,000 | 0.02% |
| ETF MANAGERS GROUP, LLC | 52,216 | $579,000 | 0.02% |
| IHT Wealth Management, LLC | 13,000 | $146,000 | 0.02% |